Daiichi Sankyo Co., Ltd.

4568

JP3475350009

Pharmaceuticals

Market Closed - Japan Exchange Other stock markets 02:00:00 2024-04-25 am EDT			5-day change	1st Jan Change
4,766 ^JPY	+0.78%		+5.07%	+23.09%

10:20am	AstraZeneca upbeat as cancer drugs underpin sales growth	AN
Apr. 19	Middle East Tensions Dent Asian Stock Markets	MT

Daiichi Sankyo Company, Limited Provides Earnings Guidance for the Full Year Ending March 31, 2022

July 30, 2021 at 12:00 am EDT

Daiichi Sankyo Company, Limited provided earnings guidance for the full year ending March 31, 2021. For the year, the company expects revenue of JPY 990,000 million, operating profit of JPY 70,000 million, profit for the year of JPY 50,000 million or JPY 26.09.

Latest news about Daiichi Sankyo Co., Ltd.

AstraZeneca upbeat as cancer drugs underpin sales growth	04:20am	AN
Middle East Tensions Dent Asian Stock Markets	Apr. 19	MT
Roche’s HER2-Low Metastatic Breast Cancer Diagnostic Test Secures CE Mark	Apr. 10	MT
AstraZeneca's Enhertu Receives FDA Approval for HER2-Positive Solid Tumor Indication	Apr. 08	MT
AstraZeneca, Daiichi Sankyo Secure Accelerated US FDA Clearance for Cancer Treatment Enhertu	Apr. 08	MT
AstraZeneca: US approval extended for Enhertu	Apr. 08	CF
AstraZeneca hails neurological data for Ultomiris, Soliris	Apr. 08	AN
AstraZeneca, Daiichi Sankyo's Solid Tumor Drug Wins US FDA's Accelerated Approval	Apr. 08	MT
Astra hails neurology data; CVS flags cyberattack	Apr. 08	AN
AstraZeneca's, Daiichi's Enhertu receives US FDA approval	Apr. 08	AN
AstraZeneca Wins US Approval for Solid Tumor Treatment	Apr. 07	MT
Astrazeneca and Daiichi Sankyo's ENHERTU Receives Approval in US as First Tumor-Agnostic HER2-Directed Therapy for Previously Treated Patients with Metastatic HER2-Positive Solid Tumors	Apr. 05	CI
US FDA approves Daiichi, AstraZeneca drug for treatment of solid tumors	Apr. 05	RE
Merck, Daiichi Sankyo Dose First Person in Phase 2/3 Trial of Raludotatug Deruxtecan to Treat Ovarian Cancer	Apr. 03	MT
Merck: 1st patient in raludotatug study	Apr. 03	CF
Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer	Apr. 03	CI
AstraZeneca, Daiichi make US progress with licence approvals	Apr. 03	AN
FTSE 100 Ends Lower; UK Manufacturing Sector Escapes Contraction	Apr. 02	MT
AstraZeneca, Daiichi Sankyo Say US FDA Accepts Their Biologics License Application for Breast Cancer Treatment	Apr. 02	MT
AstraZeneca and Daiichi make US progress with latest licence approvals	Apr. 02	AN
AstraZeneca, Daiichi Sankyo's Jointly Developed Breast Cancer Treatment Accepted for US Regulatory Review	Apr. 02	MT
HSBC in special payout on Canada sale; Astra FDA win	Apr. 02	AN
AstraZeneca, Daiichi Sankyo Seek US FDA Approval for Breast Cancer Drug	Apr. 02	MT
Datopotamab Deruxtecan Biologics License Application Accepted in the U.S. for Patients with Previously Treated Metastatic HR Positive, HER2 Negative Breast Cancer	Apr. 02	CI
Esperion, Daiichi Get EU Committee Recommendation For Nilemdo, Nustendi Label Update	Mar. 22	MT

Chart Daiichi Sankyo Co., Ltd.

Duration

Period

More charts

Company Profile

Daiichi Sankyo Company specializes in developing, manufacturing and marketing pharmaceutical products. Net sales break down by activity as follows: - sale of medicines (99.8%): prescription medicines (92.8% of net sales) and OTC medicines (7.2%) primarily for the treatment of thrombotic disorders, tumors, diabetes and rheumatoid arthritis; - other (0.2%): primarily real estate activities. Net sales are distributed geographically as follows: Japan (64.1%), North America (17.2%), Europe (9.7%) and other (9%).

Sector

Pharmaceuticals

Calendar

2024-04-24 - Q4 2023 Earnings Release

Related indices

Nikkei 225

More about the company

Income Statement Evolution

More financial data

Ratings for Daiichi Sankyo Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

A-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

4,729 JPY

Average target price

5,620 JPY

Spread / Average Target

+18.84%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DAIICHI SANKYO CO., LTD.	+23.09%	58.47B
ELI LILLY AND COMPANY	+25.61%	660B
NOVO NORDISK A/S	+23.89%	562B
JOHNSON & JOHNSON	-5.24%	358B
MERCK & CO., INC.	+16.49%	322B
ABBVIE INC.	+8.28%	297B
ASTRAZENECA PLC	+12.88%	219B
ROCHE HOLDING AG	-9.78%	196B
NOVARTIS AG	+6.79%	199B
PFIZER, INC.	-8.75%	149B

Other Pharmaceuticals

Daiichi Sankyo Co., Ltd.

Equities

4568

JP3475350009

Pharmaceuticals

Daiichi Sankyo Company, Limited Provides Earnings Guidance for the Full Year Ending March 31, 2022

EPS Revisions